<DOC>
	<DOCNO>NCT01697072</DOCNO>
	<brief_summary>This phase 3 , multicenter , randomize , double-blind , placebo control study epirubicin , cisplatin &amp; capecitabine ( ECX ) rilotumumab placebo untreated advance MET-positive gastric gastroesophageal junction ( GEJ ) adenocarcinoma</brief_summary>
	<brief_title>First-Line Treatment Locally Advanced Metastatic Mesenchymal Epithelial Transition Factor ( MET ) - Positive Gastric , Lower Esophageal , Gastroesophageal Junction ( GEJ ) Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Pathologically confirm unresectable locally advanced metastatic gastric GEJ adenocarcinoma •Eastern Cooperative Oncology Group ( ECOG ) performance status ( 0 1 ) Tumor METpositive immunohistochemistry ( IHC ) Evaluable ( measurable nonmeasurable ) disease Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 criterion Key exclusion criterion : Human Epidermal Growth Factor Receptor 2 ( HER2 ) overexpressing locally advance metastatic gastric GEJ adenocarcinoma •Previous systemic therapy locally advance metastatic gastric GEJ adenocarcinoma Less 6 month elapse completion prior neoadjuvant adjuvant chemotherapy chemoradiotherapy randomization Previous treatment anthracyclines must exceed total cumulative dose epirubicin 400 mg/m2 Squamous cell histology Left ventricular ejection fraction ( LVEF ) &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>First Line Treatment Gastroesophageal Junction ( GEJ )</keyword>
	<keyword>Gastroesophageal Junction Cancer ( GEJ )</keyword>
	<keyword>GEJ Cancer</keyword>
</DOC>